Detalles de la búsqueda
1.
Personalized Risk-Benefit Ratio Adaptation of Breast Cancer Care at the Epicenter of COVID-19 Outbreak.
Oncologist
; 25(7): e1013-e1020, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32412693
2.
Management of Trastuzumab Deruxtecan-related nausea and vomiting in real-world practice.
Front Oncol
; 14: 1374547, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38529378
3.
A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer.
Breast Cancer Res Treat
; 139(2): 411-9, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23649189
4.
An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer.
Breast
; 21(6): 716-23, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-23022045
5.
Antiangiogenic strategies in breast cancer management.
Crit Rev Oncol Hematol
; 76(1): 13-35, 2010 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-20702105
6.
Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma: pooled analysis of 2 consecutive trials.
Cancer
; 109(6): 1060-7, 2007 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-17295293
7.
Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial.
Cancer
; 101(4): 704-12, 2004 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-15305399
Resultados
1 -
7
de 7
1
Próxima >
>>